Former Insys Therapeutics CEO Michael Babich is expected to plead guilty to charges involving the company's effort to expand the market for his its opioid product.
In documents filed this week by federal prosecutors, Babich was expected to plead guilty in one count of conspiracy and a second count of mail fraud in a case involving the company's Subsys pain relief drug, according to the Arizona Republic.
Babich was among seven total Insys executives, including the company's founder John Kapor,…
